BioLegend (part of Revvity) develops world-class, cutting-edge antibodies, recombinant proteins, bioassays, and other reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, California. Our mission is to accelerate research and discovery by providing the highest quality products at an outstanding value, along with superior customer service and technical support. BioLegend was incorporated in June, 2002. The founder and CEO of BioLegend, Gene Lay, D.V.M., who was also the co-founder of PharMingen. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.